Vanda Pharmaceuticals Inc. (VM4)
XDUS 
Summary
VM4 Chart
Vanda: Next Phase Of Fanapt Growth Might Be With Bysanti Advancement
Vanda Pharma's revenue growth is driven by Fanapt's label expansion to bipolar I disorder, offsetting declines in HETLIOZ and PONVORY sales. Upcoming catalysts include Bysanti's PDUFA date for bipolar I/schizophrenia (Feb 2026) and phase 3 data for MDD, plus tradipitant's motion sickness PDUFA (Dec 2025). Vanda's pipeline features a selective JAK2 inhibitor for polycythemia vera, recently granted Orphan Drug Designation, targeting a growing $2B market by 2032.
Vanda Pharmaceuticals Inc. (VNDA) Q2 2025 Earnings Call Transcript
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q2 2025 Earnings Call July 31, 2025 8:00 AM ET Company Participants Kevin Patrick Moran - Senior VP, CFO & Treasurer Mihael H. Polymeropoulos - Founder, President, CEO & Chairman of The Board Conference Call Participants Lin Tsai - Jefferies LLC, Research Division Olivia Simone Brayer - Cantor Fitzgerald & Co., Research Division Raghuram Selvaraju - H.C.
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.08 per share a year ago.
Vanda Pharmaceuticals Inc. Dividends
Vanda Pharmaceuticals Inc. Earnings
| 5 Nov 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 5 Nov 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 29 Oct 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
| 31 Jul 2025 Date | | - Cons. EPS | - EPS |
| 30 Jul 2025 Date | | - Cons. EPS | - EPS |
| 5 Nov 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 5 Nov 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 29 Oct 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
| 31 Jul 2025 Date | | - Cons. EPS | - EPS |
| 30 Jul 2025 Date | | - Cons. EPS | - EPS |
Vanda Pharmaceuticals Inc. (VM4) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Vanda Pharmaceuticals Inc. ever had a stock split?
Vanda Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mihael H. Polymeropoulos CEO | XDUS Exchange | US9216591084 ISIN |
| US Country | 368 Employees | - Last Dividend | - Last Split | 12 Apr 2006 IPO Date |
Overview
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for addressing high unmet medical needs on a global scale. With a focus on conditions that affect sleep-wake disorders, schizophrenia, and a variety of other medical conditions, Vanda Pharmaceuticals seeks to improve the quality of life for patients worldwide. Since its incorporation in 2002, and headquartered in Washington, D.C., the company has made significant strides in bringing novel treatments to the market and continues to expand its robust pipeline of promising therapeutic candidates.
Products and Services
- HETLIOZ (tasimelteon) – Marketed for the treatment of non-24-hour sleep-wake disorders. The pipeline for HETLIOZ includes potential applications for:
- Jet lag disorder
- Insomnia
- Delayed sleep phase disorder
- Sleep disturbances in autism spectrum disorder
- Pediatric Non-24
- Fanapt (iloperidone) oral tablets – Marketed for the treatment of schizophrenia, with ongoing development for:
- Bipolar I disorder
- Parkinson's disease psychosis
- A long-acting injectable (LAI) formulation for schizophrenia
- Tradipitant (VLY-686) – A small molecule neurokinin-1 receptor (NK-1R) antagonist in development for:
- Gastroparesis
- Motion sickness
- Atopic dermatitis
- COVID-19 pneumonia
- VTR-297 – A small molecule histone deacetylase inhibitor being studied for:
- Hematologic malignancies
- Various oncology indications
- VQW-765 – A small molecule nicotinic acetylcholine receptor partial agonist under investigation for:
- Performance anxiety
- Psychiatric disorders
- VHX-896 – An active metabolite of iloperidone in development.
- Antisense Oligonucleotide Molecules – Under investigation for various indications.
- Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activators and Inhibitors, including:
- VSJ-110 for the treatment of dry eye and ocular inflammation
- VPO-227 for treating secretory diarrhea disorders such as cholera
Contact Information
